SouthernWorldwide.com – A groundbreaking new blood test, known as Stockholm3, is showing significant promise in detecting aggressive prostate cancer cases earlier and more effectively than current screening methods.
This innovative test has demonstrated superior performance in clinical trials compared to the traditional prostate-specific antigen (PSA) test, a long-standing standard in prostate cancer screening.
A recent study, published in the esteemed Annals of Internal Medicine, involved researchers from the Karolinska Institutet in Sweden. They evaluated the efficacy of the Stockholm3 test on over 12,000 men, predominantly of Swedish and European descent, aged between 50 and 74.
NEW PROSTATE CANCER TEST PINPOINTS DISEASE BETTER THAN PSA OPTION, STUDY FINDS
All participants underwent both PSA and Stockholm3 testing. Their health was monitored for a period of two years. Within this follow-up timeframe, 443 men were diagnosed with aggressive prostate cancer.
The Stockholm3 test successfully identified 90% of these aggressive prostate cancer cases. In contrast, the conventional PSA tests achieved a detection rate of only 74% for aggressive disease.
Significantly, Stockholm3 missed “substantially fewer” serious cancer cases when compared to PSA. The study also noted that the number of men incorrectly classified as high-risk was comparable between both testing methods, as indicated by a press release.
Thorgerdur Palsdottir, a researcher at the Department of Medical Epidemiology and Biostatistics at Karolinska Institutet, highlighted a major hurdle in prostate cancer management. She stated that a key challenge lies in accurately identifying cases that are “truly dangerous.”
‘DILBERT’ CREATOR’S DESPERATE PLEA SHINES SPOTLIGHT ON ALTERNATIVE PROSTATE CANCER DRUG
“Our findings indicate that Stockholm3 is more effective at identifying aggressive cancer cases than PSA, without leading to an increase in unnecessary follow-up procedures,” Palsdottir explained.
“These results suggest a potential shift in how prostate cancer screening is conducted,” she added. “A more precise blood test could facilitate earlier detection of aggressive disease, while simultaneously reducing the number of unnecessary follow-up examinations and procedures.”
PROSTATE CANCER SCREENING AFTER 70: EXPERTS QUESTION GUIDANCE AFTER BIDEN’S DIAGNOSIS
He confirmed that the PSA test has been the established standard for prostate cancer screening since the 1990s, despite its “well-documented limitations.”
CLICK HERE FOR MORE HEALTH STORIES
“It often leads to invasive and costly follow-up tests, contributes to the over-diagnosis of non-aggressive cancers, and, most critically, it fails to detect a significant proportion of aggressive disease,” stated Vigneswaran.
The importance of early detection is underscored by the fact that when aggressive prostate cancer is diagnosed while still confined within the prostate, the five-year survival rate approaches 100%, according to medical professionals.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
Data from the National Cancer Institute’s SEER database reveals an increase in metastatic prostate cancer over the past decade. This trend suggests that “we have not improved the early detection of aggressive, curable disease that screening is intended to identify,” Vigneswaran commented.
“The objective of screening is to detect cancers that require treatment when they are still curable, without increasing the number of men who screen positive but do not have aggressive disease,” he emphasized.
According to the researcher, Stockholm3 has the potential to decrease the need for unnecessary MRIs and biopsies.
However, the findings are not without their limitations. Vigneswaran pointed out that Stockholm3 is currently an investigational device and is not yet commercially available in the U.S.
While the test estimates a man’s risk of aggressive prostate cancer, a biopsy remains the definitive method for confirming the disease.
The company behind Stockholm3 intends to seek FDA approval for its use in routine screening. Vigneswaran stated that they will “generate the necessary evidence to support that pathway, including U.S. data.”
